Prenetics Posts Record Q1 2026 as IM8 Surges and Guidance Raised
I'm LongbridgeAI, I can summarize articles.Prenetics Group reported record Q1 2026 results, with $36.0 million in revenue driven by a sixfold year-on-year surge in IM8 sales. The company raised full-year IM8 revenue guidance to $190-$210 million and projected strong Q2 performance. Despite a widened net loss due to non-cash digital asset write-downs, operating momentum remains robust. Prenetics exited its digital asset holdings, appointed a new CFO for IM8, and plans to launch new product SKUs, signaling a strategic pivot toward scalable consumer health brands.
Introducing TipRanks MCP for Agents
- Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
- Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.
Prenetics Group ( (PRE) ) just unveiled an announcement.
On June 10, 2026, Prenetics reported record first-quarter 2026 results, with revenue from continuing operations of $36.0 million and gross profit of $23.3 million, driven largely by IM8’s $33.8 million in revenue, up 23.1% quarter-on-quarter and nearly sixfold year-on-year. The company projected second-quarter 2026 revenue of $46 million to $48 million, raised full-year 2026 IM8 revenue guidance to $190 million to $210 million, and noted that while loss for the period widened to $23.1 million, this was mainly due to non-cash fair-value losses on digital assets and warrant liabilities that did not impact operating performance.
Management highlighted strong momentum for IM8, citing May 2026 IM8 revenue of about $16.7 million, implying roughly $200 million in annualized recurring revenue, alongside a 65% group gross margin in the quarter. Prenetics also fully exited its digital asset holdings for $41.3 million, outlined plans to launch three new IM8 SKUs in hydration, creatine and kids’ gummies in the fourth quarter of 2026, and strengthened its supplements business leadership by appointing industry finance veteran Brian J. Rosin as IM8’s chief financial officer, underscoring a strategic pivot toward scalable consumer health brands.
The most recent analyst rating on (PRE) stock is a Buy
with a $36.00 price target.
To see the full list of analyst forecasts on Prenetics Group stock,
see the PRE Stock Forecast page.
Spark’s Take on PRE Stock
According to Spark, TipRanks’ AI Analyst, PRE is a Neutral.
The score is primarily held back by ongoing losses and sustained negative free cash flow despite improving revenue and gross margins. Technicals are moderately supportive with price above key moving averages, while valuation remains constrained by negative earnings and no dividend. The latest earnings call was a positive catalyst via raised guidance and strong subscription/unit-economics trends, but elevated marketing spend and guidance/reporting clarity issues temper the upside.
To see Spark’s full report on PRE stock,
click here.
More about Prenetics Group
Prenetics Global Limited is a consumer health sciences company listed on Nasdaq and based in Hong Kong, best known as the parent of IM8, a premium health and longevity supplements brand, and CircleDNA. The company focuses on higher-margin, recurring revenue consumer health products, positioning IM8 as its primary growth engine in the global wellness and longevity market.
Average Trading Volume: 213,817
Technical Sentiment Signal: Buy
Current Market Cap: $352.2M
Find detailed analytics on PRE stock on TipRanks’ Stock Analysis page.